2025 Peptide Research Highlights: The Studies That Actually Mattered
2025 was a massive year for peptide science. Not just incremental improvements, but genuine paradigm shifts in how we understand these compounds.
I've been tracking the literature all year. Here's what stood out from the noise.
1. BPC-157 Finally Got Human Safety Data
The biggest complaint about BPC-157 has always been "no human trials." That changed this year.
A pilot study published in Alternative Therapies tested IV BPC-157 in humans at doses up to 20mg. The results: no adverse events, no concerning changes in vital signs, cardiac function, liver enzymes, or kidney markers. Plasma levels returned to baseline within 24 hours, confirming its rapid clearance.
Why it matters: This isn't efficacy data, but it's the first real human safety data we have. It validates what practitioners have observed anecdotally for years, that BPC-157 appears well-tolerated. The door is now open for larger efficacy trials.
A separate systematic review in the Orthopaedic Journal of Sports Medicine analyzed 36 studies from 1993-2024 and mapped out the mechanism more clearly. BPC-157 works through multiple pathways: enhancing growth hormone receptor expression, promoting angiogenesis, and reducing inflammatory cytokines. Clinical experience suggests it acts like a biological "reset button" for injured tissue.
2. The GLP-1 Wars Got Settled (And Retatrutide Just Changed Everything)
We finally got head-to-head data comparing tirzepatide vs semaglutide, and then retatrutide dropped a bomb.
The SURMOUNT-5 trial results published in NEJM in May showed tirzepatide produced 20.2% weight loss at 72 weeks versus 13.7% for semaglutide. That's not a marginal difference, that's a 50% improvement in efficacy.
But then on December 11, Eli Lilly released TRIUMPH-4 Phase 3 results for retatrutide, and it blew everything else away:
Retatrutide Phase 3 Results (TRIUMPH-4):
12mg dose: 28.7% body weight reduction (average 71.2 lbs lost)
9mg dose: 26.4% body weight reduction
Placebo: 2.1% reduction
75.8% reduction in knee osteoarthritis pain
14% of patients were completely free of knee pain at week 68
The updated hierarchy:
Semaglutide: ~15% body weight reduction
Tirzepatide: ~20-22% reduction (dual agonist)
Retatrutide: ~28.7% reduction (triple agonist)
Real-world data from academic obesity clinics confirmed tirzepatide and semaglutide findings hold up outside controlled trials. Patients persistent for 12+ months saw median weight loss of 14.4%.
The safety signal to watch: Retatrutide showed a new side effect called dysesthesia (abnormal touch sensation) in 8.8% of patients on 9mg and 20.9% on 12mg, compared to 0.7% on placebo. This wasn't seen in Phase 2, so it's worth monitoring in the 7 additional Phase 3 readouts expected in 2026.
What practitioners are watching: Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. Analysts predict FDA approval in 2027 with potential sales of $15.6 billion by 2031. Still not available outside clinical trials, but the efficacy signal is unprecedented.
3. Mitochondrial Peptides Went Mainstream
MOTS-c and SS-31 moved from obscure longevity compounds to serious research targets in 2025.
A study published in Experimental & Molecular Medicine showed MOTS-c acts as a senotherapeutic agent, specifically preventing pancreatic islet cell senescence in diabetic models. Research on age-related decline shows blood MOTS-c levels in young people are about 21% higher than in old-aged people, suggesting supplementation may help reverse age-related dysfunction.
The clinical insight: MOTS-c levels decline approximately 50% between ages 20 and 70. This correlates with the metabolic dysfunction we see in aging: insulin resistance, decreased exercise capacity, mitochondrial dysfunction. Practitioners report that restoring MOTS-c levels appears to improve metabolic markers and energy.
SS-31 (Elamipretide) showed continued promise in cardiovascular and neurodegenerative applications. Research confirms it works by binding to cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain and reducing oxidative damage at the source. Phase II trials showed improvements in exercise capacity and heart function.
The stack angle: SS-31 provides immediate mitochondrial membrane stabilization while MOTS-c coordinates longer-term metabolic adaptation. Clinical experience suggests they work synergistically when combined.
4. AI Is Redesigning Peptide Discovery
This is the sleeper story of 2025 that will reshape everything.
According to research published in Frontiers in Pharmacology, 78% of peptide-drug conjugates entering clinical trials since 2022 have utilized AI-optimized components, compared to less than 15% before 2020. We're not talking about marginal improvements, we're talking about entirely new compound classes that wouldn't have been discovered through traditional methods.
The Institute for Protein Design released RFpeptides, an AI tool that designs novel macrocyclic peptides from scratch. They demonstrated it could create high-affinity binders for targets with no known structure, just from amino acid sequences. The work was published in Nature Chemical Biology in June 2025.
Why this matters for the community: The peptides we'll be discussing in 2026 and beyond may be AI-designed compounds that don't exist in nature. Faster discovery, better optimization, and the ability to target "undruggable" proteins.
5. Oral Peptide Delivery Got Real
The holy grail of peptide therapeutics has always been oral delivery. In 2025, we saw real progress.
Oral semaglutide (Rybelsus) proved the concept works. Now multiple oral peptides are in Phase III trials, including Icotrokinra for psoriasis and Enlicitide for hypercholesterolemia.
The bioavailability problem (most peptides have less than 1% oral absorption) is being solved through multiple strategies: pH-responsive hydrogels, mucoadhesive nanoparticles, and novel formulation technologies.
The practical implication: We may be entering an era where injection-only peptides become available as oral formulations. This would dramatically increase accessibility and compliance.
6. New Brain-Targeting Peptide Discovered
A four-amino acid peptide called CAQK showed powerful brain-protective effects in traumatic brain injury models. It's able to cross the blood-brain barrier via standard IV administration and specifically targets injured brain tissue.
In both mice and pig models (pigs have brain structure closer to humans), it reduced inflammation, decreased cell death, and improved functional recovery. The research was published in EMBO Molecular Medicine and the company Aivocode is preparing for Phase I human trials with FDA.
Why it's interesting: Most peptides don't cross the blood-brain barrier effectively. CAQK appears to specifically home in on injured brain regions due to its affinity for a protein that becomes abundant after trauma. This opens up possibilities for treating conditions that were previously difficult to reach.
What This Means For Your Protocols
BPC-157 users: The safety data validates what you've likely experienced. Still not FDA-approved, but the research foundation is getting stronger.
GLP-1 users: If semaglutide isn't working as well as expected, tirzepatide is the evidence-based upgrade. Retatrutide is showing nearly double the efficacy of semaglutide in Phase 3, but it's not available yet outside clinical trials. Watch for the dysesthesia signal as more data comes out.
Longevity-focused users: MOTS-c and SS-31 are worth serious consideration for mitochondrial optimization. The data on age-related decline in MOTS-c levels is compelling.
Everyone: 2026 will likely bring 7 more retatrutide Phase 3 readouts plus AI-designed peptides we haven't seen before. The discovery pipeline is accelerating.
The Bigger Picture
2025 marked a transition year for peptide therapeutics. We moved from "interesting animal data" to "real human trials" for multiple compounds. AI accelerated discovery. Oral delivery became practical.
The next 5 years will likely see more peptide drugs approved than the previous 20 combined.
Stay informed. Stay skeptical of hype. Follow the evidence.
This post is for research and educational purposes only. Not medical advice. Consult a healthcare provider before starting any protocol.
